CSIMC Recommends NHI Price Listing for 15 APIs/20 Products

At a general meeting on September 7, the Central Social Insurance Medical Council (CSIMC; Chuikyo) recommended NHI price listing for 15 APIs (active pharmaceutical ingredients)/20 products, including AstraZeneca’s proton pump inhibitor (PPI) Nexium capsule 10 mg and 20 mg (esomeprazole magnesium) and Astellas Pharma’s treatment for overactive bladder Betanis Tablet 25 mg and 50 mg (mirabegron). The adrenal hormone preparation EpiPen Injection 0.15 mg and 0.3 mg (adrenaline) will be added to the NHI price list on September 22. Other products will be included in the NHI price list on September 12.
> Read full story


Japanese Drug Makers Working to Increase Pace of Drug Discovery by Optimizing Operations at Research Centers


Drug requiring guidance:

The Column

Taking Pride in Small Things Makes Big Things Possible


Kyoto University, Astellas Aim to Develop Immunological Disease Cures, 11 Target Molecules Now under Screening(Aug.21)
MTPC, AZ Ink Research Collaboration Deal in Diabetic Nephropathy(Aug.21)
Report of Changes to Package Inserts to Be Required Before Providing Revised Information to Healthcare Professionals Under New System(Aug.21)
Health Sciences Council to Include “Program to Promote Joint Drug Development by Govt and Private Sector” in FY2015 Budget Request(Aug.21)
Eisai Files Fycompa for Primary Generalized Tonic-Clonic Seizures in US, Europe(Aug.21)

Most Read

PMDA Will Prosp...
Health, Science...
Health Ministry...
First Meeting o...
148 Blopress Ge...

News Calendar